Final data from SURMOUNT-3 (tirzepatide), real-world experience with the latest antiobesity drugs, a standards-of-care document in the works, and more will be featured at Obesity Week 2023 in Dallas.
Were the GLP-1 receptor agonist drug s apparent benefits in STEP-HFpEF due solely to weight loss or additional mechanisms? The trial offers a clue, experts say.
Revisional-RYGB examined for GERD and weight-loss failure medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.